Lung damage in the elderly is more complex than expected

New findings by a new UCLA project will provide a new way to bridge the gap in the field of lung cancer research providing new insights into the intensity and duration of secondary negative lung tumors.

The researchers tested infusions of a novel experimental drug three-methoxy-prednisone in three patients who had moderate-risk late-stage lung cancer.

Our findings are particularly relevant because lung cancer is the most common type of cancer among both men and women and among people of advanced ages said lead author Jo Anne Pickens an associate professor of lung cancer at UCLA. We believe that infusing these drugs during the day of relapse can be beneficial particularly for patients with small unmet clinical trials.

Pickens noted that the drug was developed by biotechnology company Flow which was acquired by Eli Lilly and Co.s Brain Tumor Research Institute in 2019 after a decade-long merger.

The research was published in The Lancet Oncology.

These findings provide a new approach in lung cancer disease research said first author Tamiko Tanaka a graduate student in Pickens laboratory. We would like to do additional studies in human cell and mouse models to demonstrate that infusions of a novel infusions drug yield more durable and more abundant tumors in patients with late-stage lung cancer.

With about 1. 3 million lung cancer patients in the United States the UCLA Lung Cancer Program operates the largest and most advanced lung cancer clinical trial registry in the country providing eventually targeted therapy to approximately 2500 patients.

It is very exciting that the infusions of 3-methoxy-prednisone were effective in the three patients with early-stage low-grade small untreated lung cancer said study first author Jingshan Li a postdoctoral fellow in Pickens laboratory. Hopefully drug candidates are developed and safe for these patients and good lung cancer survival as a result.

Preliminary research showed that patients disease was fairly responsive to infusions of the drug drawing many patients back to the hospital. UCLA will now expand those studies in further research with a larger number of patients. It also will partner with Flow to test the drug in combination with other treatments.

This new drug is safe and has good progression-free and survival potential in animal models that resemble lung cancers Pickens said. We have it plated in the clinical trial registry at UCLA and we can see that patients are responding. Infusion of this drug is a good option because it had therapeutic benefit. Inflated infusions allow us to see if this drug works well compared to traditional chemotherapy.

Preliminary results from the research are expected to be presented in October 2020 at the 60th Annual Meeting of the National Academy of Sciences.